Meeder Asset Management Inc. purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 4,497 shares of the biopharmaceutical company’s stock, valued at approximately $70,000.
Several other institutional investors and hedge funds have also modified their holdings of the business. Gallacher Capital Management LLC purchased a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth $288,000. Arizona State Retirement System lifted its stake in shares of Catalyst Pharmaceuticals by 2.2% during the 2nd quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company’s stock valued at $461,000 after buying an additional 654 shares in the last quarter. TD Asset Management Inc purchased a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter valued at $254,000. Mesirow Institutional Investment Management Inc. lifted its stake in shares of Catalyst Pharmaceuticals by 29.9% during the 2nd quarter. Mesirow Institutional Investment Management Inc. now owns 934,234 shares of the biopharmaceutical company’s stock valued at $14,471,000 after buying an additional 215,130 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Catalyst Pharmaceuticals by 3.5% during the 2nd quarter. Rhumbline Advisers now owns 323,769 shares of the biopharmaceutical company’s stock valued at $5,015,000 after buying an additional 10,805 shares in the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.
Catalyst Pharmaceuticals Stock Down 0.3 %
Catalyst Pharmaceuticals stock opened at $20.22 on Friday. The company’s 50-day moving average price is $18.42 and its 200-day moving average price is $16.64. The company has a market cap of $2.40 billion, a PE ratio of 37.44, a price-to-earnings-growth ratio of 3.10 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a twelve month low of $11.55 and a twelve month high of $20.87.
Insider Activity
In other news, insider Carmen Jeffrey Del sold 36,058 shares of the company’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $18.42, for a total transaction of $664,188.36. Following the sale, the insider now directly owns 12,369 shares in the company, valued at approximately $227,836.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Carmen Jeffrey Del sold 36,058 shares of the stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $18.42, for a total value of $664,188.36. Following the sale, the insider now directly owns 12,369 shares of the company’s stock, valued at approximately $227,836.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David S. Tierney sold 15,000 shares of the stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the completion of the sale, the director now directly owns 348,874 shares in the company, valued at $7,012,367.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 201,058 shares of company stock worth $4,018,188. 11.00% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on CPRX. Truist Financial lifted their target price on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, August 9th. HC Wainwright lifted their target price on shares of Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, August 12th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 9th. Citigroup boosted their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $29.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, June 6th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $29.50.
Read Our Latest Analysis on CPRX
Catalyst Pharmaceuticals Profile
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Featured Stories
- Five stocks we like better than Catalyst Pharmaceuticals
- Best Aerospace Stocks Investing
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
- What is the NASDAQ Stock Exchange?
- Kroger Stock is a Win-Win for Buy-and-Hold Investors
- What to Know About Investing in Penny Stocks
- MarketBeat Week in Review – 9/9 – 9/13
Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report).
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.